Related references
Note: Only part of the references are listed.Development and validation of a simple LC-MS/MS method for simultaneous determination of moxifloxacin, levofloxacin, prothionamide, pyrazinamide and ethambutol in human plasma
Xubin Zheng et al.
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2020)
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis
Andrew J. Nunn et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Limited Sampling Strategies Using Linear Regression and the Bayesian Approach for Therapeutic Drug Monitoring of Moxifloxacin in Tuberculosis Patients
Simone H. J. van den Elsen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Management of patients with multidrug-resistant tuberculosis
C. Lange et al.
INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE (2019)
Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report
Sergey Borisov et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Minimum Inhibitory Concentrations of Fluoroquinolones and Pyrazinamide Susceptibility Correlate to Clinical Improvement in Multidrug-resistant Tuberculosis Patients: A Nationwide Swedish Cohort Study Over 2 Decades
Lina Davies Forsman et al.
CLINICAL INFECTIOUS DISEASES (2019)
Levofloxacin pharmacokinetics, pharmacodynamics and outcome in multidrug-resistant tuberculosis patients
Samiksha Ghimire et al.
EUROPEAN RESPIRATORY JOURNAL (2019)
Dose optimization of moxifloxacin and linezolid against tuberculosis using mathematical modeling and simulation
M. Tobias Heinrichs et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Increased Doses Lead to Higher Drug Exposures of Levofloxacin for Treatment of Tuberculosis
Charles A. Peloquin et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Levofloxacin Pharmacokinetics/Pharmacodynamics, Dosing, Susceptibility Breakpoints, and Artificial Intelligence in the Treatment of Multidrug-resistant Tuberculosis
Devyani Deshpande et al.
CLINICAL INFECTIOUS DISEASES (2018)
Population Pharmacokinetic Model and Limited Sampling Strategies for Personalized Dosing of Levofloxacin in Tuberculosis Patients
Simone H. J. van den Elsen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Plasma concentrations of second-line antituberculosis drugs in relation to minimum inhibitory concentrations in multidrug-resistant tuberculosis patients in China: a study protocol of a prospective observational cohort study
Lina Davies Forsman et al.
BMJ OPEN (2018)
Therapeutic drug monitoring to prevent acquired drug resistance of fluoroquinolones in the treatment of tuberculosis
Lina Davies Forsman et al.
EUROPEAN RESPIRATORY JOURNAL (2017)
Population-based resistance of Mycobacterium tuberculosis isolates to pyrazinamide and fluoroquinolones: results from a multicountry surveillance project
Matteo Zignol et al.
LANCET INFECTIOUS DISEASES (2016)
The association between sterilizing activity and drug distribution into tuberculosis lesions
Brendan Prideaux et al.
NATURE MEDICINE (2015)
Moxifloxacin Population Pharmacokinetics and Model-Based Comparison of Efficacy between Moxifloxacin and Ofloxacin in African Patients
Simbarashe P. Zvada et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Extensive Drug Resistance Acquired During Treatment of Multidrug-Resistant Tuberculosis
J. Peter Cegielski et al.
CLINICAL INFECTIOUS DISEASES (2014)
Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes
Jotam G. Pasipanodya et al.
JOURNAL OF INFECTIOUS DISEASES (2013)
Evaluation of moxifloxacin for the treatment of tuberculosis: 3 years of experience
A. D. Pranger et al.
EUROPEAN RESPIRATORY JOURNAL (2011)
Selection of a moxifloxacin dose that suppresses drug resistance in Mycobacterium tuberculosis, by use of an in vitro pharmacodynamic infection model and mathematical modeling
T Gumbo et al.
JOURNAL OF INFECTIOUS DISEASES (2004)
Share Paper
